| Species |
Mouse |
| Protein Construction |
| His |
IL-17B (His21-Phe180)_x000D_
Accession # Q9QXT6 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
19.1 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 19.1 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PB, 2mM DTT, 300mM NaCl, 200mM Arginine(pH 7.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. |
| Synonyms |
IL-17B; Cytokine CX1; IL20; interleukin 17B; interleukin 20; MGC138900; MGC138901; NIRF; ZCYTO7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
